- Militant, among 3 killed in J&K forest shootout
- 15 dead Maoists fished out of Maharashtra river; toll 37
- Saroj Khan backs casting couch, says film industry 'at least' gives jobs
- Pakistan hockey hero seeks heart transplant in India
- India strongly raises terrorism issue at SCO FMs' meet in China
- Trump admin toughens H1-B visa procedure
- PM launches Rashtriya Gram Swaraj Abhiyan
- Kathua rape-murder: Cop, SPO arrested by SIT move J-K HC
HEALTH & FITNESS
Apollo Hospitals ties up with RMS Regrow for cell-based therapy
Apollo Hospitals has partnered with Mumbai-based Regenerative Medical Services (RMS) Regrow to offer a safe and cost-effective cell therapy for cartilage and bone problems for the first time in India.
The partnership will make the cell-based treatment available across all 40 centres of Apollo Hospitals, including Apollo Spectra Hospitals and Apollo clinics in India, the hospital chain said at an event here on Monday.
RMS Regrow, the first "Make in India" company in cell therapy technology, has two treatments: Chondron ACI for knees or cartilage problems and Ossron Autologous Osteoblast Implantation (ABI) for hip joints.
"Nearly 65-70 per cent of people above the age of 40 experience joint problems. The cell therapy may help postpone the need for a replacement surgery and with proper rehabilitation it will also enable a patient to resume normal routine in nearly three months," Prathap C Reddy, Founder-Chairman of Apollo Hospitals told the media.
With the cell-therapy technique, damage to the cartilage can be repaired after the new cultured cartilage is put back into one's knees.
However, for individuals at an advanced stage of osteoarthritis, replacement surgeries will be the best mode of treatment as their cartilages may not be able to regrow.
"Both Ossron and Chondron are efficient in treating a young arthritic knee with sports injuries, accidents and can is an alternative treatment to hip replacements or knee replacements," said Satyen Sanghavi, Chief Scientific Officer at RMS Regrow.
"In the future, the cell therapy-based treatment can also be extended to lengthening of limbs or bones or for maxillofacial defects (defects of the head and neck)," he added.
The company also received a market authorisation approval from the Drug Controller General of India (DGCI) in April this year.
Further, the treatment cost "in India, will be Rs 3.5-4 lakh per patient, which is less than 10 per cent of the cost abroad and will be available in all our hospitals in six months," Reddy said.
- Asthma, hay fever may up mental disorder risk 24 Apr 2018 | IANS
- Mechanism behind spread of deadly fungal infection found 23 Apr 2018 | PTI
- Drinking water may boost mental skills in exercising elderly 23 Apr 2018 | IANS
- Medication use increases in newly-diagnosed dementia patients 23 Apr 2018 | IANS
- How cancer-causing virus clings to our DNA decoded 22 Apr 2018 | PTI
- Heart patients who walk faster hospitalised less 22 Apr 2018 | IANS
- Stronger people have sharper brains: Study 21 Apr 2018 | PTI
- Beer belly bad for your heart 21 Apr 2018 | IANS
- Running marathon boosts immunity: Study 21 Apr 2018 | IANS
- Lack of Vitamin D may up diabetes risk by 5 times 20 Apr 2018 | IANS
Sunday EditionView All
22 Apr 2018 | PTI | Ahmedabad
A mild tremor measuring 3.7 on the Richter scale was felt in parts of south Gujarat, including Bharuch and Surat districts, though no damage was reported, officials said...
STATE EDITIONSView All
24 Apr 2018 | Staff Reporter | Bhopal
The first meeting of Acharya Shankar Ekta Nyas was held under the chairmanship of Chief Minister Shivraj Singh Chouhan on Monday at Chief Minister’s residence. Discussion on setting up statue, museum, institution establishment, premises construction, architectural style and vision, rules of the trust, administrative requirements, financial management and formation of executive committee was held in the meeting...